A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 713-719

  Giorgio, Carmelo G ^a   Pappalardo, Alessandro ^b   Russo, Antonio ^c   Santini, Daniele ^d,h   Di Rosa, Carlo ^a   Di Salvo, Carmela ^a   Castorina, Sergio ^e   Marletta, Franco ^f   Bellissima, Giuseppe ^a   Palermo, Nuccio ^a   Scuderi, Concetto ^a   Bordonaro, Roberto ^g  

^a Gravina Hospital   (Italy)

^b CCD GB Morgagni   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d University of Catania ^*  (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f GARIBALDI HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Concomitant chemoradiotherapy; Elderly; Induction chemotherapy; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORPHENIRAMINE; DEXAMETHASONE; PACLITAXEL; RANITIDINE; SEROTONIN ANTAGONIST;

ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 34548299786     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328082558a     Document Type: Article

References (37)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-1389.
3. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22:4626-4631.
4. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59:1874-1881.
5. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
6. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
7. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994; 10 (Suppl 1) S239-S244.
8. Curran WJ, Scott CB, Langer CJ. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III NSCLC: RTOGroup (RTOG) 9410. Proc Am Soc Clin Oncol 2003; 22:621 [abstract 2499].
9. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
10. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46:87-98.
11. Gridelli C, Maione P, Rossi A, Ciardiello F, Raben D. Treatment of locally advanced non-small cell lung cancer in the elderly. Curr Opin Oncol 2005; 17:130-134.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer (Phila) 1981; 47:207-214.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989; 10:1-10.
14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-M156.
15. Saliba D, Elliot M, Rubestein LZ, Solomon DH, Young RT, Kamberg CJ, et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49:1691-1699.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method for of classifying prognostic comorbidity in longitudinal series. Development and validation. J Chronics Dis 1987; 40:373-383.
17. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748-1756.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
19. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2001; 51:19-20.
20. National Cancer Institute. Common toxicity criteria (CTC). Version 2.0. Bethesda: National Cancer Institute; 1999.
21. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancérologie NPC 95 study. J Clin Oncol 2005; 23:5910-5917.
22. Huber RM, Schmidit M, Lang S, Borgmeier A, Huber RM, Flentje M, et al. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB). Proc Am Soc Clin Oncol 2003; 22:622 [abstract 2501].
23. Vokes EE, Herndon JE III, Kelley MY. Induction chemotherapy followed by concomitant chemoradiotherapy versus chemoradiotherapy alone for regionally advanced unresectable non-small cell lung cancer: initial analysis of a randomized phase III trial. J Clin Oncol 2004; 22:14s [abstract 7005].
24. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23:5883-5891.
25. Hayakawa K, Mitsuhashi N, Katano S, Saito Y, Nakayama Y, Sakurai H, et al. High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer 2001; 32:81-88.
26. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, et al. Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 1998; 16:3078-3081.
27. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Milisavljevic S, et al. Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. Int J Radiat Oncol Biol Phys 1998; 42:1091-1096.
28. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326:524-530.
29. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17:4-11.
30. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201-3206.
31. Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48:1475-1482.
32. Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45:1143-1149.
33. Langer CJ, Hsu C, Curran WJ, Komaki R, Lee JS, Byhardt R, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG 9410). Proc Am Soc Clin Oncol 2002; 21:299a [abstract 1193].
34. Rocha Lima CM, Herndon JE II, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002; 94:181-187.
35. Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, et al. Concomitant radio-chemotherapy based on platinum compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006; 17:473-483.
36. Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:100-107.
37. Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, et al. Is trimodality approach better than bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 2006; 53:23-30.